-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Given Average Rating of "Moderate Buy" by Analysts
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Given Average Rating of "Moderate Buy" by Analysts
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) has been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $8.69.
A number of equities analysts have commented on DNA shares. Bank of America lowered Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research note on Wednesday, May 18th. BTIG Research raised their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Tuesday, August 16th. Raymond James raised their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an "outperform" rating in a research note on Tuesday, August 16th. Finally, Jefferies Financial Group lowered their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a research note on Thursday, June 16th.
Get Ginkgo Bioworks alerts:Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lincoln National Corp bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $26,000. Atria Wealth Solutions Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $30,000. Cetera Investment Advisers bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $33,000. First Horizon Advisors Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $38,000. Finally, Endurance Wealth Management Inc. increased its position in Ginkgo Bioworks by 100.0% in the 1st quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company's stock valued at $40,000 after buying an additional 5,000 shares in the last quarter. 53.37% of the stock is owned by institutional investors and hedge funds.
Ginkgo Bioworks Stock Performance
NYSE:DNA opened at $2.99 on Wednesday. The stock has a market cap of $5.34 billion, a P/E ratio of -1.53 and a beta of 1.84. The stock has a 50 day simple moving average of $2.98 and a 200 day simple moving average of $3.10. The company has a current ratio of 11.84, a quick ratio of 11.78 and a debt-to-equity ratio of 0.03. Ginkgo Bioworks has a 1-year low of $2.09 and a 1-year high of $15.86.Ginkgo Bioworks Company Profile
(Get Rating)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
Featured Stories
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) has been given a consensus recommendation of "Moderate Buy" by the eight brokerages that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $8.69.
据MarketBeat报道，银杏生物工程控股公司(纽约证券交易所代码：DNA-GET评级)已被目前报道该公司的八家经纪公司一致给予“适度买入”的建议。一位股票研究分析师对该股的评级为卖出，一位分析师给出了持有评级，五位分析师给出了该公司的买入评级。在过去一年发布该股报告的分析师中，12个月目标价的平均水平为8.69美元。
A number of equities analysts have commented on DNA shares. Bank of America lowered Ginkgo Bioworks from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research note on Wednesday, May 18th. BTIG Research raised their price objective on Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Tuesday, August 16th. Raymond James raised their price objective on Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an "outperform" rating in a research note on Tuesday, August 16th. Finally, Jefferies Financial Group lowered their price objective on Ginkgo Bioworks from $11.50 to $4.35 in a research note on Thursday, June 16th.
许多股票分析师对DNA股票发表了评论。美国银行将Ginkgo Bioworks的评级从中性下调至表现不佳，并为该股设定了3.00美元的目标价。在5月18日星期三的一份研究报告中。BTIG Research在8月16日周二的一份研究报告中将银杏生物工场的目标价从5.00美元上调至6.00美元，并给予该股“买入”评级。雷蒙德·詹姆斯在8月16日星期二的一份研究报告中将银杏生物科技公司的目标价从11.50美元上调至14.50美元，并给出了“跑赢大盘”的评级。最后，杰富瑞金融集团在6月16日星期四的一份研究报告中将银杏生物工程的目标价从11.50美元下调至4.35美元。
Institutional Inflows and Outflows
机构资金流入和流出
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lincoln National Corp bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $26,000. Atria Wealth Solutions Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $30,000. Cetera Investment Advisers bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $33,000. First Horizon Advisors Inc. bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at about $38,000. Finally, Endurance Wealth Management Inc. increased its position in Ginkgo Bioworks by 100.0% in the 1st quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company's stock valued at $40,000 after buying an additional 5,000 shares in the last quarter. 53.37% of the stock is owned by institutional investors and hedge funds.
一些对冲基金和其他机构投资者最近改变了他们在该业务中的头寸。林肯国家公司在第二季度购买了银杏生物工程公司的新股份，价值约2.6万美元。Atria Wealth Solutions Inc.在第二季度以约3万美元的价格购买了银杏生物科技公司的新股份。其他投资顾问公司在第二季度购买了银杏生物工程公司的新股份，价值约3.3万美元。第一地平线顾问公司(First Horizon Advisors Inc.)在第二季度以约3.8万美元的价格购买了银杏生物科技公司的新股份。最后，耐力财富管理公司在第一季度将其在银杏生物工程公司的头寸增加了100.0%。耐力财富管理公司现在持有10,000股该公司股票，价值40,000美元，在上个季度又购买了5,000股。53.37%的股票由机构投资者和对冲基金持有。
Ginkgo Bioworks Stock Performance
银杏生物工场股票表现
Ginkgo Bioworks Company Profile
银杏生物工程公司简介
(Get Rating)
(获取评级)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
银杏生物工程控股公司及其子公司开发细胞编程平台。它的平台用于对细胞进行编程，以实现产品的生物生产，如新型疗法、食品配料和从石油中提取的化学品。该公司服务于各种终端市场，包括特种化学品、农业、食品、消费品和药品。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- These 3 Reports Will Tell Us Much About the Current Economy
- Is Five Below Trying to Punch Too High?
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 免费获取StockNews.com关于银杏生物工程(DNA)的研究报告
- 这三份报告将告诉我们许多关于当前经济的情况。
- 下面的五个是不是打得太高了？
- 这就是现在对标准普尔500指数的预期
- 关于甲骨文的FQ1报告，你需要知道的两件事
- 波动市场的三只价值股
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
接受《银杏生物工场日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对银杏生物工程和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧